# PRODUCT INFORMATION



# Astragaloside IV

Item No. 12069

CAS Registry No.: 84687-43-4

Formal Name:  $(3\beta,6\alpha,16\beta,20R,24S)-20,24-epoxy-16,25-$ 

dihydroxy-3-(β-D-xylopyranosyloxy)-9,19-

cyclolanostan-6-yl, β-D-glucopyranoside

Synonyms: AS-IV, AST-IV MF:  $C_{41}H_{68}O_{14}$ FW: 785.0 **Purity:** ≥95%

Supplied as: A crystalline solid

Storage: -20°C Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

# **Laboratory Procedures**

Astragaloside IV is supplied as a crystalline solid. A stock solution may be made by dissolving the astragaloside IV in the solvent of choice. Astragaloside IV is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of astragaloside IV in these solvents is approximately 30 and 20 mg/ml, respectively.

Astragaloside IV is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, astragaloside IV should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Astragaloside IV has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

## Description

Astragaloside IV is a bioactive saponin first isolated from the dried plant roots of the genus Astragalus, which is used in traditional Chinese medicine. 1 It dose-dependently inhibits human adenovirus type 3 (HAdV-3) in A549 cells (IC<sub>50</sub> = 23  $\mu$ M; LC<sub>50</sub> = 865  $\mu$ M).<sup>2</sup> It inhibits replication of HAdV-3 and decreases HAdV-3-induced apoptosis. It has diverse protective effects for the cardiovascular, immune, digestive, and nervous systems.<sup>1,3</sup> In particular, it reduces myocardial infarct size in dogs when administered prior to coronary ligation and reduces reperfusion arrhythmias in isolated rat hearts.<sup>4</sup>

#### References

- 1. Ren, S., Zhang, H., Mu, Y., et al. Pharmacological effects of Astragaloside IV: A literature review. J. Tradit. Chin. Med. 33(3), 413-416 (2013).
- 2. Shang, L., Qu, Z., Sun, L., et al. Astragaloside IV inhibits adenovirus replication and apoptosis in A549 cells in vitro. J. Pharm. Pharmacol. 63(5), 688-694 (2011).
- Li, L., X., H., Xu, R., et al. Research review on the pharmacological effects of astragaloside IV. Fundam. Clin. Pharmacol. 31(1), 17-36 (2017).
- 4. Zhang, W.-D., Chen, H., Zhang, C., et al. Astragaloside IV from Astragalus membranaceus shows cardioprotection during myocardial ischemia in vivo and in vitro. Planta Med. 72(1), 4-8 (2006).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

## WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information Buyer agrees to purchase the m can be found on our website.

Copyright Cayman Chemical Company, 11/14/2022

## **CAYMAN CHEMICAL**

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM